DB-2304
/ DualityBio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 21, 2025
DB-2304-101: A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
(clinicaltrials.gov)
- P1/2 | N=148 | Recruiting | Sponsor: DualityBio Inc. | Phase classification: P1 ➔ P1/2 | N=106 ➔ 148
Enrollment change • Phase classification • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
March 24, 2025
DB-2304-101: A Phase 1 Study of DB-2304 in Healthy Adults and SLE Participants
(clinicaltrials.gov)
- P1 | N=106 | Recruiting | Sponsor: DualityBio Inc. | Not yet recruiting ➔ Recruiting | N=70 ➔ 106
Enrollment change • Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
September 25, 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
(ACR Convergence 2024)
- "It also reduced pDC cell surface BDCA2 level in an ADC serum concentration-dependent manner and inhibited pathogenesis in Imiquimod induced psoriasis in cynomolgus monkey. DB-2304 has clearly demonstrated greater in vitro and in vivo potency with synergistic effects on the regulation of both type I interferon genes and proinflammatory cytokines in pDCs. Taken together, these data support the clinical investigation of DB-2304 in the future."
Immunomodulating • PK/PD data • Preclinical • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Psoriasis • Systemic Lupus Erythematosus
1 to 3
Of
3
Go to page
1